International business model for non-Japanese companies using ICLEAN
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: FY2024-Q1.
1 other company's latest entry also says "Advanced".
- FY2024-Q1AdvancedAnnual report
「The additional shares acquired represented a 40.2% voting interest, bringing the voting interest to 96.6% through the transaction. The additional acquisition was conducted to enhance the corporate value of the group by expanding its business through its strong customer base centered on the pharmaceutical and biotechnology fields, as well as by pursuing growth market segments such as semiconductors and lithium batteries, where investment in India is expected to increase.」
The company additionally acquired shares in ICLEAN, raising its voting interest to 96.6%. It identifies expansion into India's semiconductor and lithium battery markets, in addition to pharmaceuticals and biotechnology, as a growth opportunity. - FY2018AdvancedAnnual report
「The purpose is to further leverage the company's agile organizational capabilities and its expertise and know-how in pharmaceutical plant facilities, expand the business through synergies with its business territory and other assets, and enhance corporate value.」
The additional acquisition and consolidation of ICLEAN, with 1 October 2017 as the business combination date, has been completed, and the company has moved into the stage of leveraging ICLEAN's expertise in pharmaceutical plant facilities and synergies with its business territory. - FY2018-Q3AdvancedAnnual report
「Voting rights held immediately before the business combination 33.55% Voting rights additionally acquired on the business combination date 28.31% Voting rights held after the acquisition 61.86%」
Additional shares in ICLEAN were acquired, with 1 October 2017 treated as the acquisition date, and ICLEAN became a consolidated subsidiary with a 61.86% voting interest. The rationale was to expand the business by leveraging its expertise in pharmaceutical plant facilities and synergies with its business territory. - FY2017-Q3RestatedAnnual report
「The company will leverage Integrated Cleanroom Technologies Private Limited, an equity-method affiliate in India, to build a new international business model targeting non-Japanese companies, primarily pharmaceutical companies, in addition to its traditional overseas business model of designing and constructing overseas expansion projects for Japanese companies itself.」
The company continues to pursue a policy of building an international business model for non-Japanese and pharmaceutical companies by leveraging its Indian equity-method affiliate. - FY2017-Q2RestatedAnnual report
「The company will leverage Integrated Cleanroom Technologies Private Limited, an equity-method affiliate in India, to build a new international business model targeting non-Japanese companies, primarily pharmaceutical companies, in addition to its traditional overseas business model of designing and constructing overseas expansion projects for Japanese companies itself.」
The company continues to pursue a policy of building an international business model for non-Japanese companies, primarily pharmaceutical companies, by leveraging its Indian equity-method affiliate. - FY2017-Q1RestatedAnnual report
「The company will leverage Integrated Cleanroom Technologies Private Limited, an equity-method affiliate in India, to build a new international business model targeting non-Japanese companies, primarily pharmaceutical companies, in addition to its traditional overseas business model of designing and constructing overseas expansion projects for Japanese companies itself.」
The company continues to pursue a policy of building an international business model for non-Japanese and pharmaceutical companies by leveraging its Indian affiliate. - FY2016First statedAnnual report
「The company will leverage ICLEAN, an equity-method affiliate in India, to build a new international business model targeting non-Japanese companies, primarily pharmaceutical companies, in addition to its traditional overseas business model of designing and constructing overseas expansion projects for Japanese companies itself.」
In addition to its traditional model for Japanese companies, the company is pursuing a model targeting non-Japanese companies, primarily pharmaceutical companies, through ICLEAN.